Paper Details

  1. Home
  2. Paper Details

A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.

Author: BaekelandtM, KristensenG B, TropéC, VergoteI B

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

In 27 patients with advanced ovarian cancer, carboplatin and hexamethylmelamine (HMM) resulted in a 71% response rate, with 25% complete response and 46% partial response. The median progression-free survival was 15.6 months, and the median cancer-related survival was 21.3 months. The most common side effect was grade 3 mental depression (15%), while other side effects were mild.
Paper Details　
Original Abstract of the Article :
27 patients with ovarian cancer FIGO stages IIc-IV were treated with carboplatin 7 x (glomerular filtration rate + 25) mg given intravenously on day 1 and hexamethylmelamine (HMM) 150 mg/m2 orally on days 2-15, every 28 days. 3 patients were not evaluable for response. Clinical response was seen in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0959-8049(95)00274-m

データ提供：米国国立医学図書館（NLM）

A Phase II Study of Carboplatin and Hexamethylmelamine for Ovarian Cancer

This research investigates the effectiveness of a combination therapy involving carboplatin and hexamethylmelamine (HMM) in treating advanced epithelial ovarian carcinoma. The researchers conducted a phase II clinical trial to evaluate the safety and efficacy of this regimen in a group of patients with advanced ovarian cancer. Their findings reveal that the combination of carboplatin and HMM demonstrates a high response rate and acceptable side effects. The study highlights the potential of this combination therapy as a valuable treatment option for advanced ovarian cancer.

A New Weapon in the Fight Against Ovarian Cancer

This research offers a potential new weapon in the fight against ovarian cancer, highlighting the efficacy of carboplatin and HMM combination therapy in achieving a high response rate with acceptable side effects. This study is like discovering a new oasis in the desert of cancer treatment, offering a promising new approach to managing this challenging disease.

The Importance of Continued Research

This study underscores the importance of continued research in the field of cancer treatment. It reminds us that there is always room for innovation and development of new therapies to improve patient outcomes. This research encourages us to continue exploring the vast desert of cancer research, seeking new solutions to alleviate suffering and improve the lives of those affected.

Dr.Camel's Conclusion

This research investigates the effectiveness of carboplatin and HMM combination therapy for advanced ovarian cancer, highlighting its potential as a valuable treatment option with a high response rate and acceptable side effects. It reminds us that ongoing research is crucial in developing new and effective therapies to combat cancer and improve patient outcomes.

Date :
  1. Date Completed 1996-02-09
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

8541099

DOI: Digital Object Identifier

10.1016/0959-8049(95)00274-m

Related Literature

Article Analysis
・Side Effects of altretamine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.